Prelude Therapeutics

Forecast & Rating5 analysts currently cover Prelude Therapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $9.20, about 88.9% upside from the current price of $4.87. Price targets range from $6.00 to $12.00 — a wide spread, showing clear disagreement over just how much Prelude Therapeutics can rise. Historically, about 31.4% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Prelude Therapeutics closely still see room for the stock to rise. Data as of Sep 18, 2026; for reference only and not investment advice.